Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 12/20 | 0.55 |
| ▸ | PPARD | Q03181 | 10/20 | 0.55 |
| ▸ | PPARG | P37231 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13810423 | 0.93 | PPARA (0.49) | PPARAPPARDPPARGKDM4ECYP2C19 | |
| SCHEMBL4334763 | 0.90 | PPARA (0.61) | PPARAPPARDPPARG | |
| SCHEMBL13810557 | 0.89 | PPARA (0.50) | PPARAPPARDPPARGMAPT | |
| SCHEMBL4486227 | 0.88 | KDM4E (0.47) | PPARAPPARDPPARGKDM4ECYP2C19 | |
| SCHEMBL4335670 | 0.88 | KDM4E (0.48) | PPARAPPARDPPARGKDM4ECYP2C19 | |
| SCHEMBL4339592 | 0.87 | KDM4E (0.46) | KDM4ECYP2C19CYP2D6CYP1A2CYP2C9 | |
| SCHEMBL4340880 | 0.86 | LDHA (0.48) | KDM4ECYP2C19CYP2D6CYP1A2MEN1 | |
| SCHEMBL13810392 | 0.84 | PPARA (0.56) | PPARAPPARDPPARGMGLLMEN1 | |
| SCHEMBL13810410 | 0.82 | KDM4E (0.47) | PPARAPPARDPPARGKDM4ECYP2C19 | |
| SCHEMBL13810409 | 0.81 | KDM4E (0.46) | KDM4ECYP2C19CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | PPARA 339/4885PPARD 753/4885PPARG 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.